Keros Therapeutics (NASDAQ:KROS) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Keros Therapeutics (NASDAQ:KROS) announced its earnings results on Wednesday. The company reported ($1.21) EPS for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.12, Briefing.com reports. The firm had revenue of $0.08 million for the quarter. During the same period in the prior year, the firm earned ($1.26) earnings per share. Keros Therapeutics’s revenue was down 97.3% on a year-over-year basis.

Keros Therapeutics Stock Down 0.4 %

KROS traded down $0.22 on Thursday, reaching $58.02. The company’s stock had a trading volume of 110,247 shares, compared to its average volume of 401,106. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -11.20 and a beta of 1.32. Keros Therapeutics has a fifty-two week low of $27.02 and a fifty-two week high of $73.00. The stock has a 50 day moving average of $62.95 and a two-hundred day moving average of $49.58.

Analysts Set New Price Targets

KROS has been the topic of several research reports. William Blair reissued an “outperform” rating on shares of Keros Therapeutics in a research note on Wednesday, February 21st. Piper Sandler reaffirmed an “overweight” rating and set a $105.00 target price on shares of Keros Therapeutics in a research note on Wednesday, March 27th. Wedbush reaffirmed an “outperform” rating and issued a $86.00 target price on shares of Keros Therapeutics in a research report on Thursday, February 29th. Truist Financial reissued a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research note on Wednesday, March 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Thursday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $86.00.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.